OAM
ONC icon

Oppenheimer Asset Management’s BeOne Medicines Ltd ONC Stock Holding History

Oppenheimer Asset Management’s Portfolio ONC Stock Details ONC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$10.2M Buy
35,781
+3,249
+10% +$957K 0.11% 211
2026
Q1 		$9.66M Buy
32,532
+2,443
+8% +$791K 0.11% 210
2025
Q4 		$9.14M Sell
30,089
-1,585
-5% -$519K 0.11% 207
2025
Q3 		$10.8M Buy
31,674
+2,137
+7% +$649K 0.12% 194
2025
Q2 		$7.15M Sell
29,537
-622
-2% -$153K 0.08% 267
2025
Q1 		$8.21M Sell
30,159
-786
-3% -$184K 0.1% 223
2024
Q4 		$5.72M Buy
30,945
+518
+2% +$106K 0.07% 299
2024
Q3 		$6.83M Buy
30,427
+3,503
+13% +$630K 0.08% 261
2024
Q2 		$3.84M Buy
26,924
+8,800
+49% +$1.36M 0.05% 369
2024
Q1 		$2.83M Buy
18,124
+1,507
+9% +$243K 0.04% 400
2023
Q4 		$3M Buy
16,617
+2,816
+20% +$509K 0.04% 411
2023
Q3 		$2.48M Buy
13,801
+1,986
+17% +$393K 0.04% 422
2023
Q2 		$2.11M Buy
11,815
+430
+4% +$99K 0.03% 495
2023
Q1 		$2.45M Buy
11,385
+97
+0.9% +$23.3K 0.04% 439
2022
Q4 		$2.48M Sell
11,288
-653
-5% -$120K 0.04% 423
2022
Q3 		$1.61M Sell
11,941
-262
-2% -$45K 0.03% 510
2022
Q2 		$1.98M Buy
12,203
+256
+2% +$40K 0.03% 468
2022
Q1 		$2.25M Sell
11,947
-1,291
-10% -$274K 0.03% 498
2021
Q4 		$3.59M Buy
13,238
+259
+2% +$87.4K 0.05% 381
2021
Q3 		$4.71M Buy
12,979
+7
+0.1% +$2.29K 0.07% 313
2021
Q2 		$4.45M Buy
12,972
+539
+4% +$179K 0.06% 324
2021
Q1 		$4.33M Sell
12,433
-947
-7% -$314K 0.07% 316
2020
Q4 		$3.46M Buy
13,380
+427
+3% +$118K 0.06% 349
2020
Q3 		$3.71M Buy
12,953
+504
+4% +$118K 0.07% 300
2020
Q2 		$2.35M Buy
12,449
+122
+1% +$19.9K 0.05% 368
2020
Q1 		$1.52M Buy
12,327
+10,660
+639% +$1.67M 0.04% 409
2019
Q4 		$276K Sell
1,667
-261
-14% -$43.4K 0.01% 980
2019
Q3 		$236K Sell
1,928
-49
-2% -$6.51K 0.01% 1003
2019
Q2 		$245K Sell
1,977
-309
-14% -$39.2K 0.01% 1001
2019
Q1 		$302K Sell
2,286
-559
-20% -$75.4K 0.01% 938
2018
Q4 		$399K Sell
2,845
-3
-0.1% -$398 0.01% 824
2018
Q3 		$490K Buy
+2,848
New +$479K 0.01% 814

Other funds holding ONC

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Oppenheimer Asset Management's ONC Position: Q2 2026 in Review

Oppenheimer Asset Management increased its BeOne Medicines Ltd (ONC) stake by 10% in Q2 2026, buying an estimated $957K and bringing the position to 35,781 shares worth $10.2M. The position accounts for 0.11% of the portfolio, ranked #211.

Oppenheimer Asset Management first reported a position in ONC in Q3 2018 and has held it in 32 quarters since. The position peaked at $10.8M in Q3 2025. 283 funds tracked by Wall St. Rank hold ONC as of Q2 2026.

  • Oppenheimer Asset Management held 35,781 shares of BeOne Medicines Ltd worth $10.2M as of Q2 2026.
  • Oppenheimer Asset Management bought 3,249 BeOne Medicines Ltd shares in Q2 2026, an estimated $957K.
  • BeOne Medicines Ltd made up 0.11% of Oppenheimer Asset Management's portfolio in Q2 2026, its #211 holding.
  • Oppenheimer Asset Management first reported a position in BeOne Medicines Ltd in Q3 2018 and has held it in 32 quarters since.
  • Oppenheimer Asset Management's BeOne Medicines Ltd position peaked at $10.8M in Q3 2025.
  • 283 funds tracked by Wall St. Rank held BeOne Medicines Ltd as of Q2 2026.

Based on Oppenheimer Asset Management's 13F filing for Q2 2026, filed 3 Aug 2026.